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From Miromatrix Medical Inc, Eden Prairie, MNIN 2008, OTT ET AL1 harvested adult rat hearts,
stripped away the cells (decellularization), and
perfused those same decellularized hearts with
neonatal rat cardiac cells. After 8 days in paced cul-
ture, the recellularized hearts beat again. Ott et al1
had developed a novel method to decellularize
and primitively recellularize an entire organ while
preserving the vasculature and extracellular matrix
(ECM) and, therefore, the overall structure of the
organ. Termed perfusion decellularization, a new
paradigm for bioengineered organs was created.
To address the need for transplantable whole
organs, the field of tissue engineering was created,
and researchers have been developing methods to
bioengineer organs for decades. Fundamentally,
an organ consists of cells living within a vascular-
ized ECM. Creating a bioengineered organ re-
quires cellularization of a human-scale scaffold.
The scaffold can be made of synthetic and/or
biologic polymers but must have the correct
functional architecture of the organ of interest.
Importantly, the scaffold plays a critical role in the
success of a bioengineered organ. By using a
xenogenic source, such as a pig, the source, age,
size, and quality of the scaffold can be controlled
tightly while providing a virtually endless supply.
At a minimum, the scaffold must have the native
architecture of the organ of interest, be able to
support cell engraftment, and promote cell sur-
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While the latter point may seem trivial, oxygen and
nutrient delivery have been a substantial challenge
to bioengineering thick ($3 mm), dense organs,
such as the liver or kidney.
While tremendous progress has been made over
the last decade in the field of tissue engineering
and regenerative medicine, especially on the
cellular level, much of the promise of using these
tools to create entirely biologic, 3-dimensional,
functional structures for implantation has re-
mained unfulfilled. Other methodologies, such as
3-dimensional printing and transgenic pigs, have
made strides but also have encountered difficulties
that have kept them distant from the clinic. The
invention and successful application of perfusion
decellularization and recellularization (decell/re-
cell) has demonstrated its potential as the keystone
technology that alters this paradigm and enables
the creation of fully biologic human organs for
transplant.
The history of the medical device industry is
awash with mechanical and electrical constructs
aimed at organ function replacement; however,
these nonbiologic devices have been largely un-
successful, because they were intended to mimic
one or more functions of a particular organ,
though not the organ in its entirety. Humans,
unlike medical devices, are not made of metal and
plastic. Medical devices have targeted the treat-
ment of a disease, while regenerative medicine has
the potential to offer a cure. If one truly wants to
replace the function of a human organ, then why
not start with a fully functional, healthy human
organ? In the thousands of instances in which
donor organs are not available for transplant,
perfusion decell/recell focuses on a 100% biologic
solution to this problem aimed at a full return to
health, as opposed to a temporary mechanical
repair.
Perfusion decellularization, as first demon-
strated in 2008,1 encompasses a method to decellu-
larize and recellularize whole or partial organs andSURGERY 1
Fig 1. Decellularization of an adult porcine heart over 48 hours. A 6-month-old porcine heart undergoing perfusion
decellularization over a period of 48 hours. The native structure and vasculature are preserved after decellularization.
After 48 hours, the heart is completely decellularized. This Figure is reproduced with permission from Miromatrix Med-
ical Inc.
Fig 2. Decellularization of an adult porcine liver over 24 hours. A 6-month-old porcine liver undergoing perfusion de-
cellularization over a period of 24 hours. The native structure and vasculature remain preserved after decellularization.
Figure is reproduced with permission from Miromatrix Medical Inc.
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method for removing all cells while maintaining
an ECM or scaffold with its original architecture,
mechanical properties, and a vascular network
capable of maintaining physiologic pressures. In
the field of regenerative medicine, biologic efforts
using porcine, bovine, and human donor material
have achieved only limited success, because they
are constrained by the available technology.
The most widely recognized method of
removing cells in use today is immersion decellu-
larization, in which an organ is placed in a
container of detergent. This method is diffusion
limited and often employs the additional use of
mechanical or enzymatic methods which damage
the capsule of the organ. Cells within the organ
begin to break down before being exposed to the
detergent, releasing various enzymes that also can
degrade important functions of the surrounding
scaffold. The end result is a partially degradedscaffold with a compromised vascular network and
an outer organ capsule that will not maintain
physiologic pressures when tested.
Perfusion decellularization is in contrast to
immersion decellularization and overcomes the
hurdles of immersion by facilitating rapid access
to the whole organ through the native vasculature
by cannulating the vasculature and perfusing a
mild detergent solution through the native blood
vessels. Because organs are dense with vascular
capillaries, most cells are located within 50–100 mm
of a capillary, resulting in an exponential increase
in the effective surface area of the detergent and
decreased time to dissolve the cellular material as
it is expelled through the venous system, as
opposed to through the organ wall or capsule. In
short, this 1 or more day process, depending on
type and size of the organ or tissue, utilizes the
organ’s natural plumbing to remove rapidly the
cells from the inside out (Figs 1 and 2).
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Seetapun and Ross 3More importantly, the end result is a completely
preserved native scaffold containing the appro-
priate microenvironment required for the intro-
duction of organ-specific cells, along with an intact
vascular network to reconnect to the patient’s
blood supply and an outer capsule capable of
maintaining physiologic pressures. These compo-
nents are critical for the later use of perfusion
recellularization, which also uses perfusion to
repopulate vascular and organ-specific regenera-
tive cells onto the organ, where they migrate to the
appropriate microenvironment (via the relevant
signaling protein markers that remain within the
perfusion decellularized scaffold) as the organs are
grown and matured in bioreactors under normal
physiologic conditions. The resulting organs then
can be transplanted utilizing the same techniques
as current organ transplantation.
Scaffolds created by perfusion decell/recell are
capable of receiving and incorporating a variety of
cell on the organ scaffold utilized. As our under-
standing of cell isolation and maintenance con-
tinues to grow, the fact that scaffolds created with
this technology are of a natural, biologic design
makes them an ideal template to support the
implantation, growth, and differentiation of stem
cells into functional tissues, organs, and bio-
identical test beds.2
In 2008, Ott et al1 reported the use of
perfusion-decellularized rat hearts to create whole
bioengineered hearts that, when reseeded with
neonatal cardiac rat cells, were able to beat syn-
chronously under electric stimulation. These
were groundbreaking results, in that not only
were they able to produce a decellularized whole
heart scaffold, but they were able to create a
beating heart by seeding the scaffold with a het-
erogeneous population of cardiac cells rather
than specific cell types. Specific cell types (such
as endothelial cells) were able to migrate to the
appropriate tissue (vascular endothelium) auton-
omously, further highlighting the importance of
preserving the native ECM during decellulariza-
tion to protect any biochemical and mechanical
cues that assist with recellularization.
Since this article was published, researchers
have continued this work in several types of organs,
including heart, kidney, liver, and lung. The ulti-
mate goal is to repopulate a decellularized organ
with a patient’s own cells, thereby avoiding any
issues of immunogenicity. To this end, researchers
are examining repopulation of decellularized scaf-
folds using various cell sources, including stem
cells. Decellularized rodent hearts have been
repopulated with various stem cells.3,4Human embryonic stem cells and cardiac pro-
genitor cells were used to demonstrate that
perfusion-decellularized cardiac scaffolds can
direct stem cell differentiation. After static culture,
seeded cells demonstrated expression of cardiac-
specific markers and expression of myosin heavy
and light chains. CD31+ cells also were identified,
suggesting differentiation of stem cells into
vascular endothelial cells.
Using perfusion decellularized mouse hearts,
another group3 demonstrated differentiation of
induced pluripotent stem cell–derived cardiovas-
cular progenitor cells into cardiomyocytes, smooth
muscle cells, and endothelial cells. After 20 days of
culture, the repopulated hearts exhibited asyn-
chronous, spontaneous contractions and limited
contraction force and were responsive to pharma-
cologic stimulation. Research also has progressed
with the perfusion decellularization of clinically
relevant porcine hearts, as well as human hearts.3
Perfusion decellularized rat kidneys have been
seeded with human endothelial cells and rat
neonatal kidney cells. After 12 days in culture,
evidence of neonatal kidney cells homing to
appropriate locations within the scaffold was
observed, such as podocytes homing to glomerular
regions. In vitro, the bioengineered kidneys were
able to excrete urine, albeit at decreased levels
compared to cadaveric kidneys. The recellularized
kidneys were transplanted orthotopically in rats
and demonstrated urine production, but with
decreased creatinine clearance with fractional
resorption of electrolytes.5
Perfusion decellularized rat livers have demon-
strated preservation of basement membranes and
key ECM constituents of the extracellular matrix
(collagen types I and IV, fibronectin, and lami-
nin).6 These livers were seeded with endothelial
cells and primary rat hepatocytes and cultured
in vitro for 10 days. Cultured organs revealed repo-
pulation with both hepatocytes and endothelial
cells and exhibited synthesis of urea and albumin,
although at decreased levels. The livers were trans-
planted briefly into rats and retained hepatic func-
tion and blood flow. Other groups have
repopulated liver scaffolds using alternative cell
sources, such as human fetal hepatocytes, stellate
cells, and human induced pluripotent stem cells.7,8
Two groups have perfusion decellularized rat
lungs and seeded them with rat fetal lung cells,
endothelial cells, and, in one case, pulmonary
epithelial cells.9,10 Histologic evaluation showed
the presence of lung-specific cell types distributed
appropriately within the scaffold. For example,
type II pneumocytes were observed within alveolar
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demonstrated gas exchange similar to native rat
lungs. Bioengineered rat lungs were transplanted
orthotopically into rats and demonstrated gas ex-
change and similar mechanical characteristics to
native lung for short periods. Several studies also
have been published examining the use of alterna-
tive cell sources, such as embryonic stem cells,
mesenchymal stem cells, human fetal lung cells,
and induced pluripotent stem cells.7,8
As highlighted here, great progress has been
made in creating whole, transplantable organs.
However, creating a whole transplantable organ is
not a trivial task, and these various research
groups---as well as one commercial company, Mir-
omatrix Medical Inc, the patent holder on perfu-
sion decell/recell---face common challenges,
including optimizing decellularization to preserve
the native mechanical and biochemical environ-
ment, identifying appropriate cell sources, recellu-
larizing the scaffold with appropriate cell numbers,
and maintaining the recellularized organ in vitro.
The promising news is that all of these chal-
lenges appear to be addressable, with some of
these challenges already being addressed today. It
is also important to note that while perfusion
decell/recell is not necessarily the only method
by which the organ transplant waiting list can be
eliminated, it likely will be the fastest and most
cost-effective. As a reminder, a bioengineered or-
gan requires both a scaffold and cells to be
functional. With other tissue engineering
methods, substantial time and money is spent
developing the scaffold so that it has both the
appropriate mechanical and biochemical environ-
ment. Perfusion decell/recell achieves this in
much less time and with fewer resources, and
yields a structurally accurate scaffold with the
native vasculature intact, thereby enabling the field
to progress toward the clinic at a much faster rate.
As bioengineered organs progress toward the
clinic, it is exciting to envision the possibilities this
creates. While the end goal of perfusion decell/
recell is the ex vivo recellularization of the decellu-
larized matrix with the intended recipient’s own
cells, thereby creating a transplantable organ and
avoiding any immunogenicity issues, there are
many clinically useful products that can be created
on the way to this eventuality.
When considering a first liver construct, it is
important to note that, at the moment, patients in
end-stage liver failure have no approved treatment
methodologies. There are no devices and no drugs,
and death is inevitable within a few months without
a transplant. In order to survive, such a patientneeds only an estimated 15–20% liver function;
and, for excellent health, only 30% liver function is
required. In addition, the liver provides a unique
(among the solid organs) “assist” to the regenera-
tive process by regenerating its own cells. These
cells are invaluable---as long as there is a viable
matrix on and within which the cells can survive.
The same sort of development path could be
applied to kidney. With the kidney, however, the
target patient population would not solely be those
awaiting an organ donor for transplant. Rather, a
substantial number of individuals currently on
dialysis could be candidates for a kidney transplant
if the supply of kidneys was unlimited. The current
paradigm of organ transplantation as a last resort
and admission to the organ transplant waiting list
only for the sickest of patients could become a
problem of the past. Kidney transplants for all of
those in need would mean a “cure,” as opposed to
years of dialysis and the attendant decline in
quality of life and health.
In conclusion, the use of perfusion decellulari-
zation as a tool to generate architecturally exact,
biochemically active scaffolds with organ-
appropriate mechanical properties should change
the landscape of regenerative medicine. In the
short duration since the first report of perfusion
decellularization, this concept has advanced the
field of tissue engineering and regenerative med-
icine from thin constructs to implanting recellu-
larized lungs, livers, and kidneys into small
animals. The advances achieved with perfusion
decell/recell are making tissue-engineered whole
organs a close reality.REFERENCES
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